Showing results (71-80 of 208) with videos related to

Sort By:
Pageof 21
Cancers|March 11, 2023
Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 StudyFabio Andreozzi, Matteo Dragani, Cyril Quivoron, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2018
Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphomaLaurent Dercle, Samy Ammari, Romain-David Seban, et al.
Oncotarget|January 7, 2017
The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphomaClémentine Sarkozy, Sarah Huet, Victoria E H Carlton, et al.
Leukemia & Lymphoma|November 28, 2017
Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendationsMartin Dreyling, Igor Aurer, Sergio Cortelazzo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin FailurePhilippe Armand, Margaret A Shipp, Vincent Ribrag, et al.
Annals of Hematology|October 7, 2021
Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA studyAlexandra-Cristina Paunescu, Christiane Bergman Copie, Sandra Malak, et al.
British Journal of Haematology|July 31, 2021
Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosisAnimesh Pardanani, Ayalew Tefferi, Tamás Masszi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 22, 2017
Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphomaJulien Lazarovici, Marie Terroir, Julia Arfi-Rouche, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 13, 2022
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib StudyMaria Lia Palomba, Guillaume Cartron, Leslie Popplewell, et al.
Anti-Cancer Drugs|February 23, 2017
Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring systemLina Benajiba, Jean-Marie Michot, Capucine Baldini, et al.
Pageof 21